Outcome of dogs with intermediate grade low mitotic index high Ki67 mast cell tumours treated with surgery and single agent lomustine

Outcome of dogs with intermediate grade low mitotic index high Ki67 mast cell tumours treated with surgery and single agent lomustine

Objectives The objective of this retrospective study was to evaluate the outcome of dogs when grade II mast cell tumour (MCT) with low mitotic index (MI) and high Ki67 were treated with adjuvant lomustine. Animals Client owned dogs with spontaneously occurring disease treated with adjuvant chemother...

Full description

Saved in:
Bibliographic Details
Published in:Australian veterinary journal Vol. 99; no. 5; pp. 146 - 151
Main Authors: Néčová, S, Mason, SL, North, SM
Format: Journal Article
Language:English
Published: Melbourne Wiley Publishing Asia Pty Ltd 01-05-2021
Wiley Subscription Services, Inc
Subjects:
Animals
CCNU
Chemotherapy
Dog Diseases - drug therapy
Dog Diseases - surgery
Dogs
Ki-67 Antigen
Ki67
lomustine
Lomustine - therapeutic use
mast cell tumour
Mast Cells
Medical records
Metastases
Metastasis
Mitotic Index - veterinary
Patients
Population studies
Radiation therapy
Retrospective Studies
Spleen
Surgery
Tumors
Ultrasound
CCNU
mast cell tumour
Ki67
chemotherapy
lomustine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives The objective of this retrospective study was to evaluate the outcome of dogs when grade II mast cell tumour (MCT) with low mitotic index (MI) and high Ki67 were treated with adjuvant lomustine. Animals Client owned dogs with spontaneously occurring disease treated with adjuvant chemotherapy for grade II mast cell tumour with low MI (≤5/10HPF) and high Ki67 (>1.8%) with no evidence of metastatic disease at presentation. Procedures Lomustine was administered every 3 weeks with three or four planned cycles. Response to treatment was assessed by regular re‐staging ultrasound with or without cytopathological examination of liver and spleen or through medical records from the referring veterinarian. Disease‐free interval (DFI) and median survival time (MST) were calculated using Kaplan–Meier method. Results Twenty‐one dogs were included. All dogs underwent surgical excision and two dogs received adjuvant radiotherapy. None of the patients developed local recurrence. Three dogs (14.3%) developed metastatic disease. The DFI of these dogs was 141, 186 and 223 days. Median follow‐up period of the whole study population was 1112 days (358–2619). MST for patients with metastatic disease was 417 days. MST of the whole group was not reached. One‐year and 2‐year survivals were 95.2% and 90.5%, respectively. Conclusions and clinical relevance This study population had low rates of tumour recurrence and improved survival compared to previously published data of similar population of dogs with low MI/high Ki67 MCT without adjuvant chemotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0005-0423
1751-0813
DOI:10.1111/avj.13059